Pricing Log in Create free account
Saturday 17 October 2026 Export CELU’s income statement to Excel — free account

Celularity, Inc.

CELU Healthcare Biotechnology

Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024. In the quarter to March 2026, revenue fell 66.3%, EPS grew 103.6%, free cash flow grew 148.4% and total debt fell 4.73%, each against the same quarter a year earlier.

1.25 0.08 −6.02%
Market cap
$43.2M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
1/9
Altman Z
−15.22
Beneish M
−5.93
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 82.04%

Capital & Financial Ratios $m

Market Cap 43.16
Revenue 18.97
Net Income (71.09)
Free Cash Flow (8.81)
Net Debt 40.74
Current Ratio 0.09 (below 1: weak)
Debt/Equity (1.17) (negative: negative equity)
P/E ratio 0.00
Fwd P/E 0.00
P/S ratio 1.92
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth (100.00%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.1×, against a ten-year median of 5.7×; over the ten years it ranged from 1.2× in 2025 to 61.4× in 2022.
P/S against its own 10 years 40.05%
10-year low 10-year high
EV/Sales against its own 10 years 43.65%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 0 1 6 0
Receivables 12 14 5 5
Inventory 6 5 1 0
Other — — — —
20 21 12 6
2023 2024 2025 Q'26
Payables 14 23 26 25
ST’ Debt 39 6 16 10
Other — 1 0 0
67 54 81 71

Compound Annual Growth %

10y 5y 3y
Sales — 13.21% 13.88%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 4 — — — —
’25 11 6 5 4 27
’24 15 12 9 18 54
’23 4 3 4 12 23
’22 6 4 4 4 18
’21 3 3 11 5 21
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 1 — — — —
’25 (3) (1) (4) (5) (13)
’24 (4) (3) 0 2 (6)
’23 (15) (11) (8) (4) (39)
’22 (34) (36) (38) (30) (138)
’21 (25) (18) (35) (32) (110)
’20 (1) 0 (46) (17) (63)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1 — — — —
’25 (3) (1) (4) (5) (13)
’24 (4) (3) 0 2 (7)
’23 (15) (11) (9) (5) (40)
’22 (36) (38) (39) (30) (143)
’21 (27) (20) (36) (34) (116)
’20 (1) 0 (64) (26) (91)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.03 — — — —
’25 (0.84) (1.02) (0.88) (0.85) (3.58)
’24 (1.03) (0.30) (0.73) (0.59) (2.64)
’23 (4.10) (2.70) (5.00) 0.80 (11.02)
’22 (4.80) 3.20 0.30 2.29 0.95
’21 (33.99) (26.90) 4.00 (0.30) (14.90)
’20 6.15 (12.28) (25.15) (81.77) (113.06)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 97.00 93.00 43.90 10.49 1.59 1.30 1.00

Analyst estimates 2026–2028

Powerpack
High — — — 100.10 121.70 134.00 131.86 13.40 7.97 4.35
People
People Employees — — — — — 225 225 120 123 115
Revenue/emp, $m — — — — 0.00 0.09 0.08 0.19 0.44 0.23
Income, $m
Income, $m Revenue — — — — 14 21 18 23 54 27
Gross margin, % — — — — 65.46 54.76 (9.40) 29.66 72.36 24.39
EBT — — 0 7 (213) (100) 14 (196) (58) (92)
EBT margin, % — — 0.00 0.00 (1,491.34) (469.17) 79.03 (862.00) (106.77) (345.44)
Net income — 0 0 6 (208) (100) 14 (196) (58) (92)
Depreciation — — — — 138 9 13 122 8 7
Per share, $
Per share, $ Revenue — — 0.00 0.00 7.75 3.18 1.28 1.28 2.48 1.04
Earnings — — 0.00 6.47 (113.06) (14.90) 1.00 (11.02) (2.64) (3.47)
Cash flow — — 0.00 (1.21) (34.31) (16.42) (9.85) (2.17) (0.29) (0.52)
Capex — — 0.00 0.00 (15.11) (0.92) (0.37) (0.06) (0.01) 0.00
Free cash flow — — 0.00 (1.21) (49.42) (17.34) (10.23) (2.23) (0.30) (0.52)
Book value — — 0.03 5.50 10.16 14.83 14.22 2.30 0.40 (1.49)
Shares, m — — 1 1 2 7 14 18 22 26
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 11.45 0.00 0.00 0.00
P/S — — — — 0.00 16.09 8.80 2.19 0.84 1.07
P/B — — — — 0.00 3.45 0.79 1.22 5.15 0.00
EV/Sales — — — — 0.00 15.81 11.67 5.05 1.61 2.64
EV/FCF — — — — (2.78) (2.90) (1.47) (2.89) (13.27) (5.22)
Cash, $m
Cash, $m Operating cash flow — — 0 (1) (63) (110) (138) (39) (6) (13)
Capex — — — — (28) (6) (5) (1) 0 —
Free cash flow — — 0 (1) (91) (116) (143) (40) (7) (13)
Balance, $m
Balance, $m Working capital — — 0 1 45 33 (29) (48) (33) (68)
Total debt — — 0 — 31 31 66 39 42 48
Net debt — — 0 (1) (24) (6) 52 39 42 42
Shareholders’ equity — — 0 5 19 99 199 41 9 (38)
Returns, %
Returns, % ROA — — (1.26) 4.03 (57.63) (23.69) 3.48 (72.04) (41.86) (76.50)
ROIC — — (0.46) (25.77) 0.00 (73.05) (6.39) (150.27) (47.58) (1,070.92)
ROE — — 0.00 234.03 79.12 46.35 9.51 (163.67) (232.51) 628.23
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 1 Oct 2026

Charts ten years each

Celularity, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SER Serina Therapeutics, Inc. $45.5M — (loss-making) — (loss-making) +2,500.00% (above 0%: growing) n/m −76.82% (below 0%: shrinking) 100.00% 0.00% Compare
ANVS Annovis Bio, Inc. $44.8M — (loss-making) — — n/m −329.18% (below 0%: shrinking) — 0.00% Compare
ALDX Aldeyra Therapeutics, Inc. $44.5M — (loss-making) — — n/m +46.09% (above 0%: growing) 0.00% 0.00% Compare
CELU Celularity, Inc. $43.2M — (loss-making) — (loss-making) −66.34% (below 0%: shrinking) n/m +148.35% (above 0%: growing) 62.25% (263.47%)
DWTX Dogwood Therapeutics, Inc $42.5M — (loss-making) — — n/m +10.31% (above 0%: growing) — 0.00% Compare
SGMOQ Sangamo Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) −77.60% (below 0%: shrinking) n/m +26.21% (above 0%: growing) 100.00% (2,215.40%) Compare
VERU Veru Inc. $41.6M — (loss-making) — (loss-making) +287.06% (above 0%: growing) n/m +0.27% (above 0%: growing) 34.92% 0.00% Compare
TIL Instil Bio, Inc. $41.6M — (loss-making) — — n/m +68.62% (above 0%: growing) 0.00% 0.00% Compare
GRCE Grace Therapeutics, Inc. $41.0M — (loss-making) — (loss-making) +5,127.27% (above 0%: growing) n/m −78.85% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $42.2M — — +1,393.53% — +5.29% 17.46% 0.00%

All 614 Biotechnology stocks →

Celularity, Inc. (CELU) key facts

  • Concern: Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024.
  • Celularity, Inc. (CELU) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CELU traded at $1.25, a market capitalization of $43.2 million.
  • Return on equity was 628.2% and debt-to-equity -1.17.
  • Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −15.22 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 1, 2026.

Celularity, Inc. (CELU) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CELU · Data as of Oct 1, 2026 · For information only; not investment advice. · © 2026 stockrow.com